Ingrid Pabinger

Professor
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna
Vienna, Wien, Austria

Presentation(s):

• OC 03.4 - The Vienna CATScore for predicting VTE risk in patients with cancer: an external validation across multiple time-points

  Saturday, June 22, 2024
  13:45 – 14:00 ICT

• PB0311 - Association of ADAMTS13 activity with clinical parameters and bleeding phenotype in patients with bleeding disorder of unknown cause

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0241 - Biological aging in persons with hemophilia is associated with severity of hemophilia

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0253 - Estimating the factor VIII-equivalent activity of emicizumab using global assays of hemostasis

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0275 - Patients with mild-to-moderate bleeding disorders and bleeding disorder of unknown cause are at an increased risk for iron deficiency

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 27.2 - Comparing thrombin generation in hemophilia A and patients with non-valvular atrial fibrillation on vitamin K antagonists

  Sunday, June 23, 2024
  15:00 – 15:15 ICT

• OC 27.3 - Whole-blood rotational thromboelastometry in patients with bleeding disorder of unknown cause

  Sunday, June 23, 2024
  15:15 – 15:30 ICT

• SOA 09.2 - Risk assessment and prevention for cancer-associated VTE

  Monday, June 24, 2024
  08:25 – 08:45 ICT

• OC 32.2 - Growth differentiation factor-15 is associated with risk of major bleeding in patients with cancer: results from a prospective cohort study

  Monday, June 24, 2024
  09:45 – 10:00 ICT

• PB0921 - Association of hemostatic and inflammatory biomarkers with functional limitations three months after venous thromboembolism: Results from a prospective cohort study

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0557 - Efficacy and safety of rVIII-SingleChain in people with hemophilia A: Interim results from a non-interventional study

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0687 - Fatigue in adult patients with primary immune thrombocytopenia

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0796 - Lupus Anticoagulant-positive Patients with Thrombosis History have Altered Glycoprotein IIbIIIa Levels

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0663 - Platelet desialylation in adults with primary immune thrombocytopenia

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 42.3 - Quantifying anxiety and identifying associated factors in the post-acute phase of venous thromboembolism: Insights from a prospective cohort study

  Monday, June 24, 2024
  15:15 – 15:30 ICT

• OC 52.2 - Risk of bleeding and performance of bleeding risk scores in patients with venous thromboembolism on anticoagulation: Results from a prospective cohort study

  Tuesday, June 25, 2024
  09:45 – 10:00 ICT

• PB1010 - Activated Partial Thromboplastin Time and Factor XI are associated with risk of bleeding in patients on hemodialysis

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1194 - Daratumumab as a Well-Tolerated and Effective Treatment Option for Acquired Hemophilia A in a Frail Elderly Patient

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1439 - Incidence of venous and arterial thromboembolic events in patients with cancer receiving systemic anti-cancer therapies: results from a prospective cohort study

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1414 - Mitochondrial DNA copy number and the association with venous thromboembolism in patients with cancer

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1418 - Mucin 1 and venous thrombosis in tumor-bearing mice and patients with cancer

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1433 - Performance of established risk assessment models for the prediction of VTE in patients with cancer receiving systemic anti-cancer therapies – results from a contemporary perspective cohort study

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT